Back to discover

Protein / target

RNA demethylase ALKBH5

Encoded byALKBH5Q6P6C2Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
4
Research papers

Protein at a glance

Biological role

2-oxoglutarate-dependent dioxygenase

Strongest disease association

Breast Neoplasms

Via encoding gene ALKBH5 · Genetic evidence · score 0.38

Research activity

Emerging research

4 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Dioxygenase that specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes.

View complete UniProt function annotation

Dioxygenase that specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed:23177736, PubMed:24489119, PubMed:24616105, PubMed:24778178, PubMed:34048572, PubMed:36944332, PubMed:37257451, PubMed:37369679, PubMed:40793791). Demethylates RNA by oxidative demethylation, which requires molecular oxygen, alpha-ketoglutarate and iron (PubMed:21264265, PubMed:23177736, PubMed:24489119, PubMed:24616105, PubMed:24778178). Demethylation of m6A mRNA affects mRNA processing, translation and export (PubMed:23177736, PubMed:34048572, PubMed:36944332, PubMed:37257451). Can also demethylate N(6)-methyladenosine in single-stranded DNA (in vitro) (PubMed:24616105). Required for the late meiotic and haploid phases of spermatogenesis by mediating m6A demethylation in spermatocytes and round spermatids: m6A demethylation of target transcripts is required for correct splicing and the production of longer 3'-UTR mRNAs in male germ cells (By similarity). Involved in paraspeckle assembly, a nuclear membraneless organelle, by undergoing liquid-liquid phase separation (PubMed:37369679, PubMed:37474102). Paraspeckle assembly is coupled with m6A demethylation of RNAs, such as NEAT1 non-coding RNA (PubMed:37474102). Also acts as a negative regulator of T-cell development: inhibits gamma-delta T-cell proliferation via demethylation of JAG1 and NOTCH2 transcripts (By similarity). Inhibits regulatory T-cell (Treg) recruitment by mediating demethylation and destabilization of CCL28 mRNAs (By similarity)

Subcellular location

Nucleus speckleNucleus, nucleoplasm
Domains and Gene Ontology detail (19)

Gene Ontology

  • Cnuclear speck
  • Cnucleoplasm
  • Cnucleus
  • Cparaspeckles
  • F2-oxoglutarate-dependent dioxygenase activity
  • Fmetal ion binding
  • Fmolecular condensate scaffold activity
  • FmRNA N6-methyladenosine dioxygenase activity
  • Foxidative RNA demethylase activity
  • FRNA binding
  • Pcell differentiation
  • Pmembraneless organelle assembly

394 aa · 44 kDa · 3 isoforms

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ALKBH5

Gene-level evidence surfaced through the gene ALKBH5that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Breast Neoplasms
0.47Limited support

Genetic evidence dominant · Open Targets 0.26

Neurodegenerative Diseases
0.34Preliminary

Pathway evidence dominant · Open Targets 0.51 · no direct causal or clinical evidence

Neoplasms
0.14Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Carcinoma, Hepatocellular
0.14Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Colorectal Neoplasms
0.14Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

View evidence synthesis (5)
Breast NeoplasmsLimited support
0.47
agreement 0.330.60
Genetic74%Literature26%

Open Targets aggregate 0.26 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.34
agreement 0.160.51
Pathway99%Literature1%

Open Targets aggregate 0.51 · 2 independent evidence families · no direct causal or clinical evidence

NeoplasmsPreliminary
0.14
agreement 0.000.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

Carcinoma, HepatocellularPreliminary
0.14
agreement 0.000.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

Colorectal NeoplasmsPreliminary
0.14
agreement 0.000.41
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.51
Breast Neoplasms0.26
Neoplasms0.12
Carcinoma, Hepatocellular0.12
Colorectal Neoplasms0.12
Stomach Neoplasms0.11
Carcinoma, Non-Small-Cell Lung0.11
Arthritis, Rheumatoid0.11
Glioblastoma0.11
Leukemia, Myeloid, Acute0.11

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality LigandPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

4 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.